Originally published by our sister publication Infectious Disease Special Edition
By IDSE News Staff
The FDA press office confirmed that the agency approved the biologics license application (BLA) for the COVID-19 Vaccine, Adjuvanted (Nuvaxovid, Novavax) for immunization against SARS-CoV-2 infection, but not for all the population groups that had access to the non-mRNA vaccine under the emergency use authorization (EUA).
The vaccine has been available under the EUA since July 2022, and was